SlideShare ist ein Scribd-Unternehmen logo
1 von 33
Downloaden Sie, um offline zu lesen
THUSHARA C
1ST YEAR. M PHARM
PHARMACY PRACTICE
CONTENTS
1.DEFINITION
2.STAGES OF CKD
3.ETIOPATHOGENESIS
4.CLINICAL FEATURES
5.DIAGNOSTIC TEST RESULTS
6.THERAPY
DEFINITION
Chronic renal failure is a syndrome characterized
by progressive and irreversible deterioration of
renal function due to slow destruction of renal
parenchyma, eventually terminating in death when
sufficient number of nephrons have been damaged.
Acidosis is the major problem in CRF with
development of biochemical azotaemia and clinical
uraemia syndrome.
CKD is categorized by the level of kidney
function, based on glomerular filtration rate
(GFR), into stages 1 to 5, with each increasing
number indicating a more advanced stage of
the disease, as defined by a declining GFR.
This classification system from the National
Kidney Foundation’s Kidney Dialysis
Outcomes and Quality Initiative (K/DOQI)
also accounts for structural evidence of kidney
damage.
STAGES OF CKD
STAGE GFR DESCRIPTION TREATMENT
1 90+ Normal kidney
function, but urine
findings or
structural
abnormalities or
genetic trait point
to kidney disease
Observation,
control of blood
pressure.
2 60-89 Mildly reduced
kidney function,
and other findings
(as for stage 1)
point to kidney
disease
Observation,
control of blood
pressure and risk
factors.
3A
3B
45-59
30-44
Moderately reduced kidney function Observation, control of
blood pressure and risk
factors
4 15-29 Severely reduced kidney function Planning for end stage renal
failure
5 <15 or
on
dialysis
Very severe, or end stage kidney failure
(sometimes call established renal
failure)
Treatment choices.
ETIOPATHOGENESIS
 The diseases leading to CRF can generally be classified
into two major groups: those causing glomerular
pathology, and those causing tubulointerstitial pathology.
DISEASE CAUSING GLOMERULAR PATHOLOGY
1. Primary glomerular pathology : Glomerulonephritis,
membranous glomerulonephritis, membranoproliferative
glomerulonepritis and anti-glomerular basement
membrane nephritis.
2. SYSTEMIC GLOMERULAR PATHOLOGY: Systemic lupus
erythematosus, serum sickness nephritis and diabetic nephropathy
DISEASE CAUSING TUBULOINTERSTITIAL
PATHOLOGY
1. Vascular causes: Long-standing primary or essential
hypertension produces characteristic changes in renal arteries
and arterioles referred to as nephrosclerosis . Nephrosclerosis
causes progressive renal vascular occlusion terminating in
ischaemia and necrosis of renal tissue.
2. Infectious causes: Chronic pyelonephritis
3.Toxic causes:The most common example is intake of high doses of
analgesics such as phenacetin, aspirin and acetaminophen (chronic
analgesicnephritis). Other substances that can cause CRF after
prolonged exposure are lead, cadmium and uranium.
 4. Obstructive causes: Chronic obstruction in the urinary tract leads to
progressive damage to the nephron due to fluid backpressure. The
examples of this type of chronic injury are stones, blood clots, tumours,
strictures and enlarged prostate. Regardless of the initiating cause,
CRF evolves progressively through 4 stages:
 Decreased renal reserve
 Renal insufficiency
 Renal failure
 End stage kidney
Chronic kidney disease
CLINICAL FEATURES
 Clinical manifestations of fullblown CRF culminating in
uraemic syndrome are described under 2 main headings:
primary (renal) uraemic manifestations and secondary
(systemic or extra-renal) uraemic manifestations.
• Primary uraemic manifestations:
1. Metabolic acidosis
2. Hperkalaemia
3. Sodium water imbalance
4. Hyperuricaemia
5. Azotaemia
• Secondary uraemic (extra renal) manifestations:
1. Anaemia
2. Integumentary system: Deposit of urinary pigment
such as urochrome in the skin causes sallow-yellow
colour. The urea content in the sweat as well as in
the plasma rises. On evaporation of the perspiration,
urea remains on the facial skin as powdery ‘uraemic
frost’.
3. Cardiovascular system: Hypervolaemia and
eventually CHF
4. Respiratory system: Hypervolaemia and heart failure
cause pulmonary congestion and pulmonary oedemato
back pressure.
5. Digestive system: Azotaemia directly induces mucosalr
ulcerations in the lining of the stomach and intestines.
Subsequent bleeding can aggravate the existing
anaemia. Gastrointestinal irritation may cause nausea,
vomiting and diarrhoea.
6. Skeletal system: The skeletal manifestations of renal
failure are referred to as renal osteodystrophy .
i. Osteomalacia
ii. Osteitis fibrosa
DIAGNOSTIC TEST RESULTS
 a. Creatinine clearance may range from 0 to 90 mL/min,
reflecting renal impairment.
 b. Blood tests typically show
 (1) Elevated BUN and serum creatinine concentration.
 (2) Reduced arterial pH and bicarbonate concentration.
 (3) Reduced serum calcium level.
 (4) Increased serum potassium and phosphate levels.
 (5) Possible reduction in the serum sodium level.
 (6) Normochromic, normocytic anemia (hematocrit 20%
to 30%).
 c. Urinalysis may reveal glycosuria,
proteinuria, erythrocytes, leukocytes, and casts.
Specific gravity is fixed at 1.010.
 d. Radiographic findings. Kidney, ureter, and
bladder radiography, IV pyelography, renal
scan, renal arteriography, and
nephrotomography may be performed.
Typically, these tests reveals mall kidneys (less
than 8 cm in length).
 Structural assessments of the kidney may be
performed using a number of imaging
procedures, including:
 • ultrasonography
 • intravenous urography (IVU)
 • plain abdominal radiography
• computed tomography (CT), magnetic
resonance imaging (MRI) and magnetic
resonance angiography (MRA).
TREATMENT
• Treatment objectives:
 1. Improve patient comfort and prolong life.
 2. Treat systemic manifestations of CKD.
 3. Correct body chemistry abnormalities.
 NONPHARMACOLOGIC THERAPY
 • A low-protein diet (0.6 to 0.75 g/kg/day) can delay
progression of CKD in patients with or without diabetes,
although the benefit is relatively small. Management of the
CKD patient is generally conservative. Dietary measures and
fluid restriction relieve some symptoms of CKD and may
increase patient comfort and prolong life until dialysis or renal
transplantation is required or available.
 PHARMACOLOGICAL TREATMENT
1. Treatment of edema: Angiotensin-converting enzyme
(ACE) inhibitors and diuretics: may be given to manage
edema and CHF and to increase urine output.
a. ACE inhibitors—captopril, enalapril , lisinopril
,fosinopril
b. (1) Osmotic and loop diuretics
(2) Thiazide-like diuretics. Metolazone is the most
commonly used thiazide diuretic in CKD.
 2. Treatment of hypertension.: Antihypertensive agents
may be needed if blood pressure becomes dangerously high
as a result of edema and the high renin levels that occur in
CKD.
 a. ACE inhibitors—captopril, enalapril, lisinopril,
fosinopril
 b. calcium-channel blockers, including amlodipine and
felodipine , have similar eff ects and may be used instead of
ACE inhibitors.
 c. βAdrenergic blockers, including propranolol and
atenolol , reduce blood pressure through various
mechanisms.
 d. Other antihypertensive agents are sometimes used in the
treatment of CKD, including (-adrenergic drugs, clonidine ,
and vasodilators, such as hydralazine .
 3. Treatment of hyperphosphatemia :involves
administration of a phosphate binder, such as
aluminum hydroxide or calcium carbonate.
 4. Treatment of hypocalcemia:
 a. Oral calcium salts.
 b. Vitamin D
 Choice of agent: For the treatment of hypocalcemia
in CKD and other renal disorders, calcitriol (vitamin
D3, the active form of vitamin D) is the preferred
vitamin D supplement because of its greater efficacy
and relatively short duration of action. Other single-
entity preparations include dihydrotachysterol,
ergocalciferol , doxercalciferol and paricalcitol .
 5. Treatment of other systemic manifestations of CKD
 a. Treatment of anemia includes administration of iron (e.g.,
ferrous sulfate), folate supplements, and epoetin alfa.
 (1) Severe anemia may warrant transfusion with packed red
blood cells.
 (2) Epoetin alfa stimulates the production of red cell
progenitors and the production of hemoglobin. It also
accelerates the release of reticulocytes from the bone marrow.
 (3) Darbepoetin is an epoetin alfa analogue
 (4) Intravenous iron products may be given to replete iron
stores. Iron dextran is commonly used. Newer iron products
include sodium ferric gluconate and iron sucrose, which are
better tolerated and can be infused more rapidly compared to
iron dextran.
 b. Treatment of GI disturbances
 (1) Antiemetics help control nausea and vomiting.
 c. Treatment of skin problems. An antipruritic agent,
such as diphenhydramine, may be used to alleviate
itching.
DIALYSIS
 a. Hemodialysis: is the preferred dialysis method for patients
with a reduced peritoneal membrane, hypercatabolism, or
acute hyperkalemia.
 (1) This technique involves shunting of the patient’s blood
through a dialysis membrane containing unit for diffusion,
osmosis, and ultrafiltration. The blood is then returned to the
patient’s circulation.
 (2) Vascular access may be obtained via an arteriovenous
fistula or an external shunt.
 (3) The procedure takes only 3 to 8 hrs; most patients need
three treatments a week. With proper training, patients can
perform hemodialysis at home
 (4) The patient receives heparin during hemodialysis to
prevent clotting.
 (5) Various complications may arise, including clotting of
the hemofilter, hemorrhage, hepatitis, anemia, septicemia,
cardiovascular problems, air embolism, rapid shift s in
fluid and electrolyte balance, itching, nausea, vomiting,
headache, seizures, and aluminum osteodystrophy.

 b. Peritoneal dialysis is the preferred dialysis method for
patients with bleeding disorders and cardiovascular disease.
 (1) The peritoneum is used as a semipermeable membrane. A
plastic catheter inserted in to the peritoneum provides access
for the dialysate, which draws fluids, wastes, and electrolytes
across the peritoneal membrane by osmosis and diffusion.
 (2) Peritoneal dialysis can be carried out in three different
modes.
 (a) Intermittent peritoneal dialysis :Is an automatic cycling
mode lasting 8 to 10 hrs, performed three times a week. This
mode allows night time treatment and is appropriate for
working patients.
 (b) Continuous ambulatory peritoneal dialysis : is
performed daily for 24 hrs with four exchanges daily. The
patient can remain active during the treatment.
 (c) Continuous cyclic peritoneal dialysis : may be used if
the other two modes fail to improve creatinine clearance.
Dialysis takes place at night; the last exchange is retained
in the peritoneal cavity during the day, then drained that
evening.
 (3) Advantages of peritoneal dialysis include a lack of
serious complications, retention of normal fluid and
electrolyte balance, simplicity, reduced cost, patient
independence, and a reduced need (or no need) for heparin
administration.
 (4) Complications of peritoneal dialysis include
hyperglycemia, constipation, and inflammation or
infection at the catheter site. Also, this method carries a
high risk of peritonitis.
This surgical procedure allows some patients with end-
stage renal disease to live normal and, in many cases,
longer lives.
 a. Histocompatibility must be tested to minimize the risk
of transplant rejection and failure. Human leukocyte
antigen (HLA) type, mixed lymphocyte reactivity, and
blood group types are determined to asses
histocompatibility.
 b. Renal transplant material may be obtained from a
living donor or a cadaver.
Renal transplantation:
 c. Three types of graft rejection can occur.
(1) Hyperacute (immediate) rejection results in graft loss
within minutes to hours after transplantation.
 (a) Acute urine flow cessation and bluish or mottled
kidney discoloration are intraoperative signs of hyperacute
rejection.
 (b) Postoperative manifestations include kidney
enlargement, fever, anuria, local pain, sodium retention,
and hypertension.
 (c) Treatment for hyperacute rejection is immediate
nephrectomy.
 (2) Acute rejection may occur 4 to 60 days after
transplantation.
 (3) Chronic rejection occurs more than 60 days after
transplantation.
 (a) Signs and symptoms include low-grade fever, increased
proteinuria, azotemia, hypertension, oliguria, weight gain,
and edema.
 (b) Treatment may include alkylating agents, cyclosporine,
antilymphocyte globulin, and corticosteroids. In some cases,
nephrectomy is necessary
 d. Complications include
 (1) infection,diabetes, hepatitis, and leukopenia, resulting
from immunosuppressive therapy.
 (2) hypertension, resulting from various causes.
 (3) cancer (e.g., lymphoma, cutaneous malignancies, head
and neck cancer, leukemia, colon cancer).
(4) pancreatitis and mental and emotional disorders (e.g.,
suicidal tendencies, severe depression, brought on by
steroid therapy).
Chronic kidney disease
Chronic kidney disease

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Ckd ppt
Ckd pptCkd ppt
Ckd ppt
 
Chronic Renal Failure (End Stage Renal Failure)
Chronic Renal Failure (End Stage Renal Failure)Chronic Renal Failure (End Stage Renal Failure)
Chronic Renal Failure (End Stage Renal Failure)
 
renal failure
renal failurerenal failure
renal failure
 
Acute renal failure
Acute renal failureAcute renal failure
Acute renal failure
 
Polycystic kidney disease
Polycystic kidney diseasePolycystic kidney disease
Polycystic kidney disease
 
Ccf
CcfCcf
Ccf
 
Acute kidney injury defnition, causes,
Acute kidney injury   defnition, causes,Acute kidney injury   defnition, causes,
Acute kidney injury defnition, causes,
 
Management of chronic kidney disease
Management of chronic kidney diseaseManagement of chronic kidney disease
Management of chronic kidney disease
 
Acute Kidney Injury
Acute Kidney InjuryAcute Kidney Injury
Acute Kidney Injury
 
Chronic renal failure
Chronic renal failureChronic renal failure
Chronic renal failure
 
Renal failure management
Renal failure managementRenal failure management
Renal failure management
 
Hepatic encephalopathy
Hepatic encephalopathyHepatic encephalopathy
Hepatic encephalopathy
 
Chronic Kidney Disease
Chronic Kidney DiseaseChronic Kidney Disease
Chronic Kidney Disease
 
Renal Failure
Renal FailureRenal Failure
Renal Failure
 
End stage renal disease and its management
End stage renal disease and its managementEnd stage renal disease and its management
End stage renal disease and its management
 
Hyperkalemia
HyperkalemiaHyperkalemia
Hyperkalemia
 
Diabetes ketoacidosis
Diabetes ketoacidosisDiabetes ketoacidosis
Diabetes ketoacidosis
 
Acute kidney injury(AKI)
Acute kidney injury(AKI)Acute kidney injury(AKI)
Acute kidney injury(AKI)
 
Spotlight on indication of dialysis
Spotlight on indication of dialysisSpotlight on indication of dialysis
Spotlight on indication of dialysis
 
Management of Chronic Kidney Disorder (CKD)
Management of Chronic Kidney Disorder (CKD)Management of Chronic Kidney Disorder (CKD)
Management of Chronic Kidney Disorder (CKD)
 

Ähnlich wie Chronic kidney disease

Chronickidneydisease
Chronickidneydisease Chronickidneydisease
Chronickidneydisease Mark Gokia
 
Ckd and prevalence in India
Ckd and prevalence in IndiaCkd and prevalence in India
Ckd and prevalence in IndiaNilesh Jadhav
 
Renal disase [autosaved]
Renal disase [autosaved]Renal disase [autosaved]
Renal disase [autosaved]Ibrahim Muneim
 
Acute renal failure.
Acute renal failure.Acute renal failure.
Acute renal failure.hatch_jane
 
AKI IN ICU.pptx
AKI IN ICU.pptxAKI IN ICU.pptx
AKI IN ICU.pptxHarsh shaH
 
Acute renal failure
Acute renal failureAcute renal failure
Acute renal failurehatch_jane
 
Acute renal failure
Acute renal failureAcute renal failure
Acute renal failureMoheb Faqiri
 
ACUTE KIDNEY INJURY AND MANAGEMENT
ACUTE KIDNEY INJURY AND MANAGEMENTACUTE KIDNEY INJURY AND MANAGEMENT
ACUTE KIDNEY INJURY AND MANAGEMENTRajee Ravindran
 
GENITO-URINARY SYSTEM DISORDERS PART-1.
GENITO-URINARY SYSTEM DISORDERS PART-1.GENITO-URINARY SYSTEM DISORDERS PART-1.
GENITO-URINARY SYSTEM DISORDERS PART-1.DR .PALLAVI PATHANIA
 
Acute kidney injury
Acute kidney injury Acute kidney injury
Acute kidney injury Rajesh Mandal
 
KIDNEY FAILURE MD5 [Autosaved].pptx
KIDNEY FAILURE MD5 [Autosaved].pptxKIDNEY FAILURE MD5 [Autosaved].pptx
KIDNEY FAILURE MD5 [Autosaved].pptxerickmasele
 
ACUTE RENAL FAILURE_FINAL PRESENTATION.pptx
ACUTE RENAL FAILURE_FINAL PRESENTATION.pptxACUTE RENAL FAILURE_FINAL PRESENTATION.pptx
ACUTE RENAL FAILURE_FINAL PRESENTATION.pptxAditya Sinha
 
HEPATORENAL SYNDROME.pptx
HEPATORENAL SYNDROME.pptxHEPATORENAL SYNDROME.pptx
HEPATORENAL SYNDROME.pptxKemi Adaramola
 

Ähnlich wie Chronic kidney disease (20)

Chronickidneydisease
Chronickidneydisease Chronickidneydisease
Chronickidneydisease
 
Ckd and prevalence in India
Ckd and prevalence in IndiaCkd and prevalence in India
Ckd and prevalence in India
 
Renal disase [autosaved]
Renal disase [autosaved]Renal disase [autosaved]
Renal disase [autosaved]
 
Arf and crf
Arf and crf Arf and crf
Arf and crf
 
Acute renal failure.
Acute renal failure.Acute renal failure.
Acute renal failure.
 
AKI IN ICU.pptx
AKI IN ICU.pptxAKI IN ICU.pptx
AKI IN ICU.pptx
 
Nephrology
NephrologyNephrology
Nephrology
 
Acute renal failure
Acute renal failureAcute renal failure
Acute renal failure
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
 
Acute renal failure
Acute renal failureAcute renal failure
Acute renal failure
 
ACUTE KIDNEY INJURY AND MANAGEMENT
ACUTE KIDNEY INJURY AND MANAGEMENTACUTE KIDNEY INJURY AND MANAGEMENT
ACUTE KIDNEY INJURY AND MANAGEMENT
 
GENITO-URINARY SYSTEM DISORDERS PART-1.
GENITO-URINARY SYSTEM DISORDERS PART-1.GENITO-URINARY SYSTEM DISORDERS PART-1.
GENITO-URINARY SYSTEM DISORDERS PART-1.
 
Acute renal failure
Acute renal failure Acute renal failure
Acute renal failure
 
Hepatorenal
HepatorenalHepatorenal
Hepatorenal
 
AKI.pptx
AKI.pptxAKI.pptx
AKI.pptx
 
Acute kidney injury
Acute kidney injury Acute kidney injury
Acute kidney injury
 
KIDNEY FAILURE MD5 [Autosaved].pptx
KIDNEY FAILURE MD5 [Autosaved].pptxKIDNEY FAILURE MD5 [Autosaved].pptx
KIDNEY FAILURE MD5 [Autosaved].pptx
 
ACUTE RENAL FAILURE_FINAL PRESENTATION.pptx
ACUTE RENAL FAILURE_FINAL PRESENTATION.pptxACUTE RENAL FAILURE_FINAL PRESENTATION.pptx
ACUTE RENAL FAILURE_FINAL PRESENTATION.pptx
 
HEPATORENAL SYNDROME.pptx
HEPATORENAL SYNDROME.pptxHEPATORENAL SYNDROME.pptx
HEPATORENAL SYNDROME.pptx
 
hadout 3.ppt
hadout 3.ppthadout 3.ppt
hadout 3.ppt
 

Mehr von THUSHARA MOHAN

Hiv and opportunistic infections
Hiv and opportunistic infectionsHiv and opportunistic infections
Hiv and opportunistic infectionsTHUSHARA MOHAN
 
Comparision of thin layer chromatography and paper chromatography
Comparision of thin layer chromatography and paper chromatographyComparision of thin layer chromatography and paper chromatography
Comparision of thin layer chromatography and paper chromatographyTHUSHARA MOHAN
 
Inflammatory bowel disease
Inflammatory bowel diseaseInflammatory bowel disease
Inflammatory bowel diseaseTHUSHARA MOHAN
 
INFLAMMATORY BOWEL DISEASE
INFLAMMATORY BOWEL DISEASEINFLAMMATORY BOWEL DISEASE
INFLAMMATORY BOWEL DISEASETHUSHARA MOHAN
 
Drug information and poison information
Drug information and poison informationDrug information and poison information
Drug information and poison informationTHUSHARA MOHAN
 
Immunosuppressant drugs
Immunosuppressant drugsImmunosuppressant drugs
Immunosuppressant drugsTHUSHARA MOHAN
 
Adverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reportingAdverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reportingTHUSHARA MOHAN
 
Antibiotic resistance poster
Antibiotic resistance posterAntibiotic resistance poster
Antibiotic resistance posterTHUSHARA MOHAN
 
Uv visible instrument types
Uv visible instrument typesUv visible instrument types
Uv visible instrument typesTHUSHARA MOHAN
 

Mehr von THUSHARA MOHAN (16)

Hiv and opportunistic infections
Hiv and opportunistic infectionsHiv and opportunistic infections
Hiv and opportunistic infections
 
Comparision of thin layer chromatography and paper chromatography
Comparision of thin layer chromatography and paper chromatographyComparision of thin layer chromatography and paper chromatography
Comparision of thin layer chromatography and paper chromatography
 
WORLD LIVER DAY
WORLD LIVER DAYWORLD LIVER DAY
WORLD LIVER DAY
 
Inflammatory bowel disease
Inflammatory bowel diseaseInflammatory bowel disease
Inflammatory bowel disease
 
INFLAMMATORY BOWEL DISEASE
INFLAMMATORY BOWEL DISEASEINFLAMMATORY BOWEL DISEASE
INFLAMMATORY BOWEL DISEASE
 
Drug information and poison information
Drug information and poison informationDrug information and poison information
Drug information and poison information
 
Schizophrenia
SchizophreniaSchizophrenia
Schizophrenia
 
Immunosuppressant drugs
Immunosuppressant drugsImmunosuppressant drugs
Immunosuppressant drugs
 
Zika virus
Zika virusZika virus
Zika virus
 
Chronic renal failure
Chronic renal failureChronic renal failure
Chronic renal failure
 
Adverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reportingAdverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reporting
 
Thyroid
ThyroidThyroid
Thyroid
 
Heart failure ppt
Heart failure pptHeart failure ppt
Heart failure ppt
 
Antibiotic resistance poster
Antibiotic resistance posterAntibiotic resistance poster
Antibiotic resistance poster
 
TUBERCULOSIS
TUBERCULOSISTUBERCULOSIS
TUBERCULOSIS
 
Uv visible instrument types
Uv visible instrument typesUv visible instrument types
Uv visible instrument types
 

Kürzlich hochgeladen

How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17Celine George
 
How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17Celine George
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxheathfieldcps1
 
The Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsThe Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsEugene Lysak
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17Celine George
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxKatherine Villaluna
 
Quality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICEQuality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICESayali Powar
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and stepobaje godwin sunday
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17Celine George
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfMohonDas
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxDr. Santhosh Kumar. N
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptxraviapr7
 
3.21.24 The Origins of Black Power.pptx
3.21.24  The Origins of Black Power.pptx3.21.24  The Origins of Black Power.pptx
3.21.24 The Origins of Black Power.pptxmary850239
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxAditiChauhan701637
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice documentXsasf Sfdfasd
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfTechSoup
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...Nguyen Thanh Tu Collection
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfMohonDas
 

Kürzlich hochgeladen (20)

How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17
 
Finals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quizFinals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quiz
 
How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptx
 
The Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsThe Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George Wells
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
 
Quality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICEQuality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICE
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and step
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17
 
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdfPersonal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdf
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptx
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
 
3.21.24 The Origins of Black Power.pptx
3.21.24  The Origins of Black Power.pptx3.21.24  The Origins of Black Power.pptx
3.21.24 The Origins of Black Power.pptx
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptx
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice document
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdf
 

Chronic kidney disease

  • 1. THUSHARA C 1ST YEAR. M PHARM PHARMACY PRACTICE
  • 2. CONTENTS 1.DEFINITION 2.STAGES OF CKD 3.ETIOPATHOGENESIS 4.CLINICAL FEATURES 5.DIAGNOSTIC TEST RESULTS 6.THERAPY
  • 3. DEFINITION Chronic renal failure is a syndrome characterized by progressive and irreversible deterioration of renal function due to slow destruction of renal parenchyma, eventually terminating in death when sufficient number of nephrons have been damaged. Acidosis is the major problem in CRF with development of biochemical azotaemia and clinical uraemia syndrome.
  • 4. CKD is categorized by the level of kidney function, based on glomerular filtration rate (GFR), into stages 1 to 5, with each increasing number indicating a more advanced stage of the disease, as defined by a declining GFR. This classification system from the National Kidney Foundation’s Kidney Dialysis Outcomes and Quality Initiative (K/DOQI) also accounts for structural evidence of kidney damage.
  • 5. STAGES OF CKD STAGE GFR DESCRIPTION TREATMENT 1 90+ Normal kidney function, but urine findings or structural abnormalities or genetic trait point to kidney disease Observation, control of blood pressure. 2 60-89 Mildly reduced kidney function, and other findings (as for stage 1) point to kidney disease Observation, control of blood pressure and risk factors.
  • 6. 3A 3B 45-59 30-44 Moderately reduced kidney function Observation, control of blood pressure and risk factors 4 15-29 Severely reduced kidney function Planning for end stage renal failure 5 <15 or on dialysis Very severe, or end stage kidney failure (sometimes call established renal failure) Treatment choices.
  • 7. ETIOPATHOGENESIS  The diseases leading to CRF can generally be classified into two major groups: those causing glomerular pathology, and those causing tubulointerstitial pathology. DISEASE CAUSING GLOMERULAR PATHOLOGY 1. Primary glomerular pathology : Glomerulonephritis, membranous glomerulonephritis, membranoproliferative glomerulonepritis and anti-glomerular basement membrane nephritis.
  • 8. 2. SYSTEMIC GLOMERULAR PATHOLOGY: Systemic lupus erythematosus, serum sickness nephritis and diabetic nephropathy DISEASE CAUSING TUBULOINTERSTITIAL PATHOLOGY 1. Vascular causes: Long-standing primary or essential hypertension produces characteristic changes in renal arteries and arterioles referred to as nephrosclerosis . Nephrosclerosis causes progressive renal vascular occlusion terminating in ischaemia and necrosis of renal tissue. 2. Infectious causes: Chronic pyelonephritis
  • 9. 3.Toxic causes:The most common example is intake of high doses of analgesics such as phenacetin, aspirin and acetaminophen (chronic analgesicnephritis). Other substances that can cause CRF after prolonged exposure are lead, cadmium and uranium.  4. Obstructive causes: Chronic obstruction in the urinary tract leads to progressive damage to the nephron due to fluid backpressure. The examples of this type of chronic injury are stones, blood clots, tumours, strictures and enlarged prostate. Regardless of the initiating cause, CRF evolves progressively through 4 stages:  Decreased renal reserve  Renal insufficiency  Renal failure  End stage kidney
  • 11. CLINICAL FEATURES  Clinical manifestations of fullblown CRF culminating in uraemic syndrome are described under 2 main headings: primary (renal) uraemic manifestations and secondary (systemic or extra-renal) uraemic manifestations. • Primary uraemic manifestations: 1. Metabolic acidosis 2. Hperkalaemia 3. Sodium water imbalance 4. Hyperuricaemia 5. Azotaemia
  • 12. • Secondary uraemic (extra renal) manifestations: 1. Anaemia 2. Integumentary system: Deposit of urinary pigment such as urochrome in the skin causes sallow-yellow colour. The urea content in the sweat as well as in the plasma rises. On evaporation of the perspiration, urea remains on the facial skin as powdery ‘uraemic frost’. 3. Cardiovascular system: Hypervolaemia and eventually CHF 4. Respiratory system: Hypervolaemia and heart failure cause pulmonary congestion and pulmonary oedemato back pressure.
  • 13. 5. Digestive system: Azotaemia directly induces mucosalr ulcerations in the lining of the stomach and intestines. Subsequent bleeding can aggravate the existing anaemia. Gastrointestinal irritation may cause nausea, vomiting and diarrhoea. 6. Skeletal system: The skeletal manifestations of renal failure are referred to as renal osteodystrophy . i. Osteomalacia ii. Osteitis fibrosa
  • 14. DIAGNOSTIC TEST RESULTS  a. Creatinine clearance may range from 0 to 90 mL/min, reflecting renal impairment.  b. Blood tests typically show  (1) Elevated BUN and serum creatinine concentration.  (2) Reduced arterial pH and bicarbonate concentration.  (3) Reduced serum calcium level.  (4) Increased serum potassium and phosphate levels.  (5) Possible reduction in the serum sodium level.  (6) Normochromic, normocytic anemia (hematocrit 20% to 30%).
  • 15.  c. Urinalysis may reveal glycosuria, proteinuria, erythrocytes, leukocytes, and casts. Specific gravity is fixed at 1.010.  d. Radiographic findings. Kidney, ureter, and bladder radiography, IV pyelography, renal scan, renal arteriography, and nephrotomography may be performed. Typically, these tests reveals mall kidneys (less than 8 cm in length).
  • 16.  Structural assessments of the kidney may be performed using a number of imaging procedures, including:  • ultrasonography  • intravenous urography (IVU)  • plain abdominal radiography • computed tomography (CT), magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA).
  • 17. TREATMENT • Treatment objectives:  1. Improve patient comfort and prolong life.  2. Treat systemic manifestations of CKD.  3. Correct body chemistry abnormalities.  NONPHARMACOLOGIC THERAPY  • A low-protein diet (0.6 to 0.75 g/kg/day) can delay progression of CKD in patients with or without diabetes, although the benefit is relatively small. Management of the CKD patient is generally conservative. Dietary measures and fluid restriction relieve some symptoms of CKD and may increase patient comfort and prolong life until dialysis or renal transplantation is required or available.
  • 18.  PHARMACOLOGICAL TREATMENT 1. Treatment of edema: Angiotensin-converting enzyme (ACE) inhibitors and diuretics: may be given to manage edema and CHF and to increase urine output. a. ACE inhibitors—captopril, enalapril , lisinopril ,fosinopril b. (1) Osmotic and loop diuretics (2) Thiazide-like diuretics. Metolazone is the most commonly used thiazide diuretic in CKD.
  • 19.  2. Treatment of hypertension.: Antihypertensive agents may be needed if blood pressure becomes dangerously high as a result of edema and the high renin levels that occur in CKD.  a. ACE inhibitors—captopril, enalapril, lisinopril, fosinopril  b. calcium-channel blockers, including amlodipine and felodipine , have similar eff ects and may be used instead of ACE inhibitors.  c. βAdrenergic blockers, including propranolol and atenolol , reduce blood pressure through various mechanisms.  d. Other antihypertensive agents are sometimes used in the treatment of CKD, including (-adrenergic drugs, clonidine , and vasodilators, such as hydralazine .
  • 20.  3. Treatment of hyperphosphatemia :involves administration of a phosphate binder, such as aluminum hydroxide or calcium carbonate.  4. Treatment of hypocalcemia:  a. Oral calcium salts.  b. Vitamin D  Choice of agent: For the treatment of hypocalcemia in CKD and other renal disorders, calcitriol (vitamin D3, the active form of vitamin D) is the preferred vitamin D supplement because of its greater efficacy and relatively short duration of action. Other single- entity preparations include dihydrotachysterol, ergocalciferol , doxercalciferol and paricalcitol .
  • 21.  5. Treatment of other systemic manifestations of CKD  a. Treatment of anemia includes administration of iron (e.g., ferrous sulfate), folate supplements, and epoetin alfa.  (1) Severe anemia may warrant transfusion with packed red blood cells.  (2) Epoetin alfa stimulates the production of red cell progenitors and the production of hemoglobin. It also accelerates the release of reticulocytes from the bone marrow.  (3) Darbepoetin is an epoetin alfa analogue  (4) Intravenous iron products may be given to replete iron stores. Iron dextran is commonly used. Newer iron products include sodium ferric gluconate and iron sucrose, which are better tolerated and can be infused more rapidly compared to iron dextran.
  • 22.  b. Treatment of GI disturbances  (1) Antiemetics help control nausea and vomiting.  c. Treatment of skin problems. An antipruritic agent, such as diphenhydramine, may be used to alleviate itching.
  • 23. DIALYSIS  a. Hemodialysis: is the preferred dialysis method for patients with a reduced peritoneal membrane, hypercatabolism, or acute hyperkalemia.  (1) This technique involves shunting of the patient’s blood through a dialysis membrane containing unit for diffusion, osmosis, and ultrafiltration. The blood is then returned to the patient’s circulation.  (2) Vascular access may be obtained via an arteriovenous fistula or an external shunt.  (3) The procedure takes only 3 to 8 hrs; most patients need three treatments a week. With proper training, patients can perform hemodialysis at home
  • 24.  (4) The patient receives heparin during hemodialysis to prevent clotting.  (5) Various complications may arise, including clotting of the hemofilter, hemorrhage, hepatitis, anemia, septicemia, cardiovascular problems, air embolism, rapid shift s in fluid and electrolyte balance, itching, nausea, vomiting, headache, seizures, and aluminum osteodystrophy. 
  • 25.  b. Peritoneal dialysis is the preferred dialysis method for patients with bleeding disorders and cardiovascular disease.  (1) The peritoneum is used as a semipermeable membrane. A plastic catheter inserted in to the peritoneum provides access for the dialysate, which draws fluids, wastes, and electrolytes across the peritoneal membrane by osmosis and diffusion.  (2) Peritoneal dialysis can be carried out in three different modes.  (a) Intermittent peritoneal dialysis :Is an automatic cycling mode lasting 8 to 10 hrs, performed three times a week. This mode allows night time treatment and is appropriate for working patients.
  • 26.  (b) Continuous ambulatory peritoneal dialysis : is performed daily for 24 hrs with four exchanges daily. The patient can remain active during the treatment.  (c) Continuous cyclic peritoneal dialysis : may be used if the other two modes fail to improve creatinine clearance. Dialysis takes place at night; the last exchange is retained in the peritoneal cavity during the day, then drained that evening.  (3) Advantages of peritoneal dialysis include a lack of serious complications, retention of normal fluid and electrolyte balance, simplicity, reduced cost, patient independence, and a reduced need (or no need) for heparin administration.
  • 27.  (4) Complications of peritoneal dialysis include hyperglycemia, constipation, and inflammation or infection at the catheter site. Also, this method carries a high risk of peritonitis.
  • 28. This surgical procedure allows some patients with end- stage renal disease to live normal and, in many cases, longer lives.  a. Histocompatibility must be tested to minimize the risk of transplant rejection and failure. Human leukocyte antigen (HLA) type, mixed lymphocyte reactivity, and blood group types are determined to asses histocompatibility.  b. Renal transplant material may be obtained from a living donor or a cadaver. Renal transplantation:
  • 29.  c. Three types of graft rejection can occur. (1) Hyperacute (immediate) rejection results in graft loss within minutes to hours after transplantation.  (a) Acute urine flow cessation and bluish or mottled kidney discoloration are intraoperative signs of hyperacute rejection.  (b) Postoperative manifestations include kidney enlargement, fever, anuria, local pain, sodium retention, and hypertension.  (c) Treatment for hyperacute rejection is immediate nephrectomy.  (2) Acute rejection may occur 4 to 60 days after transplantation.
  • 30.  (3) Chronic rejection occurs more than 60 days after transplantation.  (a) Signs and symptoms include low-grade fever, increased proteinuria, azotemia, hypertension, oliguria, weight gain, and edema.  (b) Treatment may include alkylating agents, cyclosporine, antilymphocyte globulin, and corticosteroids. In some cases, nephrectomy is necessary
  • 31.  d. Complications include  (1) infection,diabetes, hepatitis, and leukopenia, resulting from immunosuppressive therapy.  (2) hypertension, resulting from various causes.  (3) cancer (e.g., lymphoma, cutaneous malignancies, head and neck cancer, leukemia, colon cancer). (4) pancreatitis and mental and emotional disorders (e.g., suicidal tendencies, severe depression, brought on by steroid therapy).